Company overview
N4 Pharma is a pre-clinical stage biopharmaceutical company developing Nuvec®, a proprietary silica nanoparticle delivery system to enhance cellular delivery of RNA therapeutics, cancer treatments, and vaccines. The non-viral, non-lipid technology protects siRNA/RNA/DNA payloads, enables targeted delivery without immune responses, and supports oral administration. The company pursues a dual-track model of platform partnering for revenue and proprietary asset development in oncology and IBD.
N4 Pharma is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include nuvec delivery system, rna therapeutics, silica nanoparticles, gene delivery, oncology biotech.
Structured facts
- Website
- https://www.n4pharma.com
- Markets served
- United States & Americas
- Keywords
- nuvec delivery system, rna therapeutics, silica nanoparticles, gene delivery, oncology biotech
Products & technologies
Therapeutic areas
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What is Nuvec® and its key capabilities?
- Nuvec® is N4 Pharma's proprietary silica nanoparticle platform for gene delivery, featuring an irregular surface that traps and protects RNA/siRNA/DNA payloads, enables targeted delivery to cancer cells like lung cancer, and supports oral administration without unwanted immune responses.
- What is the development stage and pipeline focus?
- N4 Pharma is pre-clinical with no active trials or approvals; pipeline includes oncology (e.g., lung cancer siRNA delivery), IBD (N4101 with positive in vivo data), and partnerships for RNA therapeutics and vaccines.
- What is the business model and partnerships?
- Dual-track model: partnering Nuvec® for upfront/milestone/royalty payments with partners like SRI International and Medicines Discovery Catapult; developing proprietary assets for clinic. Acquired 63.75% of Nanogenics for LipTide® platform.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
